Blends

GLOW

Prepared by the ezGLP team. Sources last checked September 5, 2026.

Also known as GHK-Cu + BPC-157 + TB-500

Routes represented in the knowledgebase: Subcutaneous (SubQ).

Educational overview

GLOW is listed in the ezGLP knowledgebase under Blends. Evidence and regulatory status can vary by formulation, route, and jurisdiction.

Category: Blends
Routes represented: Subcutaneous (SubQ)
Storage context: Follow the dispensed product or pharmacy label; storage and beyond-use time vary by formulation.

Published literature

Safety evidence

Serious or important: potential immunogenicity, aggregation, impurity, or product-quality risks.

A dependable route-specific human interaction and side-effect profile is not established; this is not evidence of no risk.

Safety evidence source

Interaction evidence

These are general, pairwise evidence notes. Green identifies the potential-synergy category, while Lv3/Lv2/Lv1 communicates evidence strength; it does not guarantee benefit or cancel a safety warning.

With BPC-157

Complementary evidenceLv2

An exploratory rat Achilles-tendon study found improved histology versus control for the combination, but no additional benefit over either peptide alone.

Interaction evidence sourceFDA TB-500 assessment

With BPC-157

Complementary evidenceLv1

The pair is proposed as complementary from separate preclinical findings involving tendon repair, angiogenic signaling, collagen, and extracellular-matrix accumulation.

Interaction evidence sourceGHK-Cu wound studyFDA peptide safety overview

With GHK-Cu

Complementary evidenceLv1

The pair is proposed as complementary from separate evidence involving thymosin-beta-4-related cell migration and GHK-Cu-associated matrix accumulation.

Interaction evidence sourceGHK-Cu wound studyFDA TB-500 assessment

With KPV

Complementary evidenceLv1

The pair is proposed as complementary through separate preclinical rationales involving tissue migration, remodeling, and inflammatory signaling.

Interaction evidence sourceKPV preclinical studyFDA KPV assessment

With KPV

Complementary evidenceLv1

The pair is proposed as complementary from separate preclinical findings involving extracellular-matrix deposition and reduced inflammatory signaling.

Interaction evidence sourceKPV preclinical studyFDA KPV assessment

Summarised from published literature for reference only, with citations to the source. Evidence is graded as reported and is not a recommendation to combine, dose, or use any compound.

For personal tracking and education only. Not medical advice, diagnosis, or treatment, and not a medical device. Peptides may be prescription-only or unapproved where you live — consult a licensed healthcare professional.